

LIFE SCIENCES **LICENSE TO CURE FOR BIOPHARMA**

Accelerate therapeutic approval, production,
and patient adoption in a global landscape



DELIVER INNOVATIVE SOLUTIONS FASTER WITH A CONSISTENT QUALITY AND COMPLIANCE PROCESS

The pharmaceutical and biotech industries are adopting highly flexible and agile methodologies to accelerate their targeted therapeutic initiatives. Leveraging an extensive, connected regulatory and quality platform can help companies consistently approach quality, compliance, and regulatory activities. The Industry Solution Experience **License to Cure for BioPharma** addresses this new industry dynamic, while still providing the certainty and effectiveness of a proven governance model.

Key Benefits:

- Reduce time-to-market and cost of market expansion
- Deliver innovative products to market faster while ensuring full regulatory compliance
- Advance your regulatory strategy: spend less time, reduce risk of non-compliance, and improve traceability
- Enhance decision making through real-time views across the lifecycle of innovation
- Ensure a consistent approach to quality, compliance, and regulatory activities across your extended ecosystem

3DEXPERIENCE Platform

Dassault Systèmes is focused on helping pharmaceutical and biotech companies effectively adapt and manage their processes to meet today's industry challenges. With the **3DEXPERIENCE®** platform and Industry Solution Experiences, Life Sciences companies can collaborate with the supply chain and regulatory agencies both pre-market and post-market through an online experience platform that helps ensure drug efficacy, safety, and quality. **License to Cure for BioPharma** enables companies to transition from a traditional product-oriented model to the delivery of therapeutic solutions using a system that enables companies to be more reactive and responsive to quickly meet market needs.

Accelerate Market Opportunity

Pharmaceutical and biotech companies strive to deliver the best medicines and therapies to their patients, but are increasingly faced with numerous challenges.

These companies, particularly those focused on small target populations, are now facing a greater frequency of regulatory authority interaction and therapeutic innovation. Today's successful BioPharma companies have realigned their business processes to facilitate rapid and ongoing innovation agility. **License to Cure for BioPharma** streamlines the submission creation and this ongoing interaction to facilitate rapid approvals in a global marketplace.

***License to Cure for BioPharma** is an Industry Solution Experience available from the app(s) represented on the **3DEXPERIENCE** platform: **BIOVIA®**

Our **3DEXPERIENCE®** platform powers our brand applications, serving 12 industries, and provides a rich portfolio of industry solution experiences.

Dassault Systèmes, the **3DEXPERIENCE®** Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes' collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 190,000 customers of all sizes in all industries in more than 140 countries. For more information, visit www.3ds.com.



TRANSFORM BUSINESS PRACTICES AND ACCELERATE INNOVATION


Fully Connected Lifecycle

The **3DEXPERIENCE** platform enables businesses to transition from historical and outdated practices to a connected and transformative environment. By focusing on the therapeutic lifecycle, the platform creates a seamless and continuous data flow to facilitate accelerated approvals, in line with the International Conference on Harmonisation paper "Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management." The transparency between early clinical activity, through manufacturing, and on to full commercialization is essential to this success.

License to Cure for BioPharma also provides decision and process traceability across all variations and changes at both the product and country level to streamline packaging processes.

License to Cure for BioPharma delivers a connected and comprehensive regulatory and quality platform to accelerate therapeutic approval, production, and patient adoption in a global landscape.

To learn more about **License to Cure for BioPharma** Industry Solution Experience provided by Dassault Systèmes, visit www.3ds.com/license-to-cure-for-biopharma.



Closed-loop information management and collaboration ensures compliance



Americas Dassault Systèmes 175 Wyman Street Waltham, Massachusetts 02451-1223 USA	Europe/Middle East/Africa Dassault Systèmes 10, rue Marcel Dassault CS 40501 78946 Vélizy-Villacoublay Cedex France	Asia-Pacific Dassault Systèmes K.K. ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6020 Japan
---	---	---